This comprehensive test maps clinically actionable mutations to FDA approved/National Comprehensive Cancer Network (NCCN) recommended standard targeted drug therapies, chemotherapies, ongoing clinical trials, and prognosis information unique to the INTEGRATED Advantage NGS. In addition, we can provide drug sensitivity and drug toxicity information to optimize the dose of drugs based on the patient’s genomic profile.

Our clinical interpretation algorithm is specific to the cancer subtype including Triple Negative Breast cancer (ER-ve/PR-ve/HER2-ve). IHC markers are incorporated with the INTEGRATED Advantage NGS panel for breast cancer, colon cancer, non-small cell lung cancer (NSCLC), melanoma expanding the resources available to make informed front-line and late stage treatment decisions in solid tumors at all stages of cancer.

DNA Encoding and Genetic Code as a Science Abstract

Highlights of our NGS Solid Tumor Panel

Targeted Therapy
Comprehensive yet highly actionable gene panel. Cancer sub-type, tissue type, and variant impact on gene and protein functions are evaluated and considered based on highly curated evidence from clinical and scientific literatures prior to therapy recommendations.
Chemotherapy and Drug Toxicity
Unique to this panel, is the robust recommendation of chemotherapies based on protein and genetic markers assisting in front-line treatment decisions. It gives indication on drug toxicity based on drug metabolism enzymes gene polymorphisms. Assist oncologists in better therapy selection.
Clinical Trials Accessibility to Patients
Our customizable report is able to highlight specific clinical trials based on specific hospital/medical system or geographic location preferences for ease of access to patients.
Enable Pathologists through TC/PC
To enable community-based Pathologist groups in their diagnostics mission, our INTEGRATED Advantage NGS panel for Breast, Colon, Non-Small Cell Lung Cancer (NSCLC), and Melanoma may be ordered as Technical Component (TC) only for client pathologists who wish to perform Professional Component (PC) of Immunohistochemistry (IHC).